Academic Articles

Academic Articles

Academic articles


  1. Strating TR, Puljevic C, Davies E, Barratt MJ, Winstock A, Ferris J. Not all home drinking is equal: A latent class analysis of drinking patterns and alcohol consumption levels following initial COVID-19 restrictions in Australia, New Zealand and the United Kingdom. Drug Alcohol Rev. 2023;42(5):1041-1053.
  2. Puljevi? C, Cossart A, Davies EL, et al. Shifts in cannabis use at the onset of the COVID-19 pandemic among Global Drug Survey respondents from 13 countries. Cannabis and Cannabinoid Research. 2023;24:145-161.
  3. Munksgaard R, Ferris JA, Winstock A, Maier LJ, Barratt MJ. Better Bang for the Buck? Generalizing Trust in Online Drug Markets. The British Journal of Criminology. 2023;63(4):906-928.
  4. Kopra EI, Ferris JA, Winstock AR, Kuypers KP, Young AH, Rucker JJ. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. J Psychopharmacol. 2023;37(7):733-748.
  5. Gilchrist G, Potts LC, Connolly DJ, et al. Experience and perpetration of intimate partner violence and abuse by gender of respondent and their current partner before and during COVID-19 restrictions in 2020: A cross-sectional study in 13 countries. BMC Public Health. 2023;23(316):1-19.
  6. Engel L, Barratt M, Ferris J, Puljevic C, Winstock A. Mescaline, Peyote and San Pedro: Is sustainability important for cacti consumers? Journal of Psychedelic Studies. 2023;7(2):135-142.
  7. De Guzman KR, Snoswell CL, Maier LJ, Winstock AR, Ferris JA, Puljevi? C. Associations between mental illness and non-medical use of prescription opioids among a sample of people who use drugs in Australia and New Zealand. Drugs: Education, Prevention and Policy. 2023;30(3):325-333.




  1. Winstock AR, Davies EL, Ferris JA, Maier LJ, Barratt MJ. Using the Global Drug Survey for harm reduction. In: EMCDDA Insights, ed. Monitoring drug use in the digital age: Studies in web surveys. Vol 26. European Monitoring Centre for Drugs and Drug Addiction; 2022.
  2. Tripathi O, Posis AI, Thompson CA, et al. In-home cannabis smoking among cannabis-using a targeted convenience sample from the Global Drug Survey respondents—with weighted estimates for US respondents. Cannabis and Cannabinoid Research. 2022.
  3. Schoeler T, Ferris J, Winstock A. Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis. Transl Psychiatry. 2022;12(1).
  4. Petranker R, Anderson T, Maier L, Barratt MJ, Ferris JA, Winstock AR. Microdosing Psychedelics: Subjective Benefits and Challenges, Substance Testing Behavior, and the Relevance of Intention. Journal of Psychopharmacology. 2022;36(1):85-96.
  5. Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms. J Psychopharmacol. 2022;36(8):965-973.
  6. Kopra E, Ferris J, Rucker J, et al. Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). Journal of Psychopharmacology. 2022;36(8):956-964.
  7. Davies EL, Puljevi? C, Gilchrist G, et al. Impacts of changes in alcohol consumption patterns during the first 2020 COVID-19 restrictions for people with and without mental health and neurodevelopmental conditions: A cross sectional study in 13 countries. International Journal of Drug Policy. 2022;101:103565.
  8. Davies EL, Foxcroft DR, Puljevi? C, Ferris JA, Winstock AR. Global comparisons of responses to alcohol health information labels: A cross sectional study of people who drink alcohol from 29 countries. Addictive Behaviors. 2022;131(107330).
  9. Craft S, Ferris J, Barratt M, et al. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. Journal of Psychopharmacology. 2022;239(5):1349–1357.
  10. Connolly D, Davies EL, Lynskey MT, et al. Differences in alcohol and other drug use and dependence between transgender and cisgender participants from the 2018 Global Drug Survey. Lgbt Health. 2022;9(8):534-542.
  11. Bellettiere J, Liles S, Posis A, et al. In-home cannabis smoking more prevalent than in-home tobacco smoking among 2019 Global Drug Survey respondents. Addictive Behaviors. 2022;125:107130.
  12. Barratt MJ, Maddox A, Smith N, et al. Who uses digital drugs? An international survey of ‘binaural beat’ consumers. Drug and Alcohol Review. 2022;41(5):1126-1130.
  13. Barratt M, Lamy FR, Engel L, et al. Exploring Televend, an innovative combination of cryptomarket and messaging app technologies for trading prohibited drugs. Drug and Alcohol Dependence. 2022;231:109243.




  1. Winstock AR, Lynskey MT, Maier L, Ferris JA, Davies E. Perceptions of cannabis health information labels among people who use cannabis in the U.S. and Canada. International Journal of Drug Policy. 2021;91.
  2. Puljevic C, Zahnow R, Benfer I, et al. Patterns of methamphetamine production among an international sample of methamphetamine ‘cooks’. Drug and Alcohol Review. 2021;40(7):1287-1293.
  3. Davies EL, Puljevic C, Connolly D, Zhuparris A, Ferris JA, Winstock AR. The world’s favourite drug: What we have learned about alcohol from over 500,000 respondents to the Global Drug Survey. In: Frings D, Albery IP, eds. The Handbook of Alcohol Use. Academic Press; 2021:17-47.
  4. Davies EL, Cooke R, Maier LJ, Winstock AR, Ferris JA. Where and what you drink is linked to how much you drink: An exploratory survey of alcohol use in 17 countries. Subst Use Misuse. 2021;56(13):1941-1950.
  5. Connolly D, Aldridge A, Davies EL, et al. Comparing transgender and cisgender experiences of being taken advantage of sexually while under the influence of alcohol and/or other drugs. Journal of Sex Research. 2021;58(9):1112-1117.



  1. Winstock AR, Ferris JA. Nitrous oxide causes peripheral neuropathy in a dose dependent manner among recreational users. Journal of Psychopharmacology. 2020;34(2):229-236.
  2. Kumar N, Puljevi? C, Ferris J, Winstock A, Barratt M. The Intersection between Spliff Usage, Tobacco Smoking, and Having the First Joint after Waking. Nature: Scientific Reports. 2020;10(1):7650-7657.
  3. Jauffret-Roustide M, Barratt M, de Dinechin S, et al. Consommation d’alcool et d’autres produits psychoactifs pendant la pandémie de Covid-19 dans la Global Drug Survey : une perspective française [Consumption of Alcohol and Other Psychoactive Drugs during the Covid-19 Pandemic in the Global Drug Survey: A French Perspective]. Psychotropes. 2020;26(2-3):209-219.
  4. Davies EL, Cooke R, Maier LJ, Winstock AR, Ferris JA. Drinking to excess and the tipping point: An international study of alcohol intoxication in 61,000 people. International Journal of Drug Policy. 2020;83(102867):1-11.
  5. Connolly D, Davies EL, Lynskey M, et al. Comparing intentions to reduce substance use and willingness to seek help among transgender and cisgender participants from the Global Drug Survey. Journal of Substance Abuse Treatment. 2020;112:86-91.




  1. Winstock AR, Holmes J, Ferris JA, Davies E. Perceptions of alcohol health warning labels in a large international cross sectional survey of people who drink alcohol. Alcohol and Alcoholism. 2019;55(3):315-322.
  2. Kumar N, Puljevi? C, Ferris J, Winstock A, Barratt MJ. Cannabis use patterns at the dawn of US cannabis reform. Journal of Cannabis Research. 2019;1(5):5.
  3. Ferris J, Puljevic C, Labhart F, Winstock A, Kuntsche E. The role of sex and age on pre-drinking: An exploratory international comparison of 27 countries. Alcohol and Alcoholism. 2019;54(4):378-385.
  4. Davies EL, Maier LJ, Winstock AR, Ferris JA. Intention to reduce drinking alcohol and preferred sources of support: An international cross-sectional study. Journal of Substance Abuse Treatment. 2019;99:80-87.
  5. Craft S, Winstock A, Ferris J, Mackie C, Lynskey MT, Freeman TP. Characterising heterogeneity in the use of different cannabis products: Latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. Psychol Med. 2019:1-10.




  1. Zahnow R, Winstock AR, Maier LJ, Levy J, Ferris J. Injecting drug use: Gendered risk. International Journal of Drug Policy. 2018;56:81-91.
  2. The Lancet. Changing the conversation to make drug use safer. Lancet. 2018;391(10134):1965.
  3. Szigeti B, Winstock AR, Erritzoe D, Maier LJ. Are ecstasy induced serotonergic alterations overestimated for the majority of users? Journal of Psychopharmacology. 2018;32(7):741-748.
  4. Maier LJ, Ferris JA, Winstock AR. Pharmacological cognitive enhancement among non-ADHD individuals-A cross-sectional study in 15 countries. International Journal of Drug Policy. 2018;58:104-112.
  5. Lawn W, Hallak JE, Crippa JA, et al. Author Correction: Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey. Sci Rep. 2018;8(1):4059.
  6. Demant D, Oviedo-Trespalacios O, Carroll JA, et al. Do people with intersecting identities report more high-risk alcohol use and lifetime substance use? Int J Public Health. 2018;63(5):621-630.
  7. Benfer I, Zahnow R, Barratt MJ, Maier L, Winstock A, Ferris J. The impact of drug policy liberalisation on willingness to seek help for problem drug use: A comparison of 20 countries. International Journal of Drug Policy. 2018;56:162-175.




  1. Zahnow R, McVeigh J, Ferris J, Winstock A. Adverse effects, help seeking and ratings of service helpfulness among anabolic androgenic steroid users. Contemporary Drug Problems. 2017;44(1):69-83.
  2. Peacock A, Bruno R, Ferris J, Winstock A. Energy drink use frequency among an international sample of people who use drugs: Associations with other substance use and well-being. Drug and Alcohol Dependence. 2017;174:70-79.
  3. Morley KI, Ferris J, Winstock AR, Lynskey MT. Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data. Pain. 2017;158(6):1138-1144.
  4. Morley KI, Ferris J, Winstock AR, Lynskey MT. (Reply) The need for a multi-pronged approach to problematic use of prescribed opioid analgesics. Pain. 2017;158(11):2277-2278.
  5. Lawn W, Hallak J, Crippa JAS, et al. Well-being, problematic alcohol consumption and acute subjective drug effects in past-year ayahuasca users: a large, international, self-selecting online survey. Nature: Scientific Reports. 2017;7(1):15201-15210.
  6. Labhart F, Ferris J, Winstock A, Kuntsche E. The country-level effects of drinking, heavy drinking and drink prices on pre-drinking: An international comparison of 25 countries. Drug and Alcohol Review. 2017;36(6):742-750.
  7. Demant D, Hides L, Kavanagh DJ, White KM, Winstock AR, Ferris J. Differences in substance use between sexual orientations in a multi-country sample: findings from the Global Drug Survey 2015. Journal of Public Health (oxf). 2017;39(3):532-541.
  8. Davies EL, Lonsdale AJ, Hennelly SE, Winstock AR, Foxcroft DR. Personalized Digital Interventions Showed no Impact on Risky Drinking in Young Adults: A Pilot Randomized Controlled Trial. Alcohol and Alcoholism. 2017;52(6):671-676.
  9. Davies EL, Conroy D, Winstock AR, Ferris J. Motivations for reducing alcohol consumption: An international survey exploring experiences that may lead to a change in drinking habits. Addictive Behaviors. 2017;75:40-46.
  10. Davies AJ, Borschmann R, Kelly SP, Ramsey J, Ferris JA, Winstock AR. The prevalence of visual symptoms in poppers users: A global survey. BMJ Open Ophthalmology. 2017;1(1):1-6.
  11. Coney L, Barratt MJ, Maier L, Ferris JA, Winstock AR. Genie in a blotter: A comparative study of LSD and LSD analogues’ effects and user profile. Human Psychopharmacology: Clinical and Experimental. 2017;32(3):1-6.
  12. Chan GCK, Hall W, Freeman TP, Ferris J, Kelly A, Winstock A. User characteristics and effect profile of Butane Hash Oil: an extremely high-potency cannabis concentrate. Drug and Alcohol Dependence. 2017;178:32-38.
  13. Barratt MJ, Ferris JA, Zahnow R, Palamar JJ, Maier LJ, Winstock AR. Moving on from representativeness: testing the utility of the Global Drug Survey. Substance Abuse: Research and Treatment. 2017;11:1-17.
  14. Ashton K, Bellis MA, Davies AR, Hughes K, Winstock A. Do emotions related to alcohol consumption differ by alcohol type? An international cross-sectional survey of emotions associated with alcohol consumption and influence on drink choice in different settings. BMJ Open. 2017;7(10).




  1. Palamar JJ, Barratt MJ, Ferris JA, Winstock AR. Correlates of new psychoactive substance use among a self-selected sample of nightclub attendees in the United States. American Journal of Addictions. 2016;25(5):400-407.
  2. Kaar S, Ferris J, Waldron J, Devaney M, Ramsey J, Winstock A. Up: the rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use. Journal of Psychopharmacology. 2016;30(4):1-7.
  3. Hindocha C, Freeman TP, Winstock AR, Lynskey MT. Vaping cannabis (marijuana) has the potential to reduce tobacco smoking in cannabis users. Addiction. 2016;111(2):375.
  4. Hindocha C, Freeman TP, Ferris JA, Lynskey MT, Winstock AR. No Smoke without tobacco: A global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front Psychiatry. 2016;7(104):1-9.
  5. Barratt MJ, Ferris JA, Winstock AR. Safer scoring? Cryptomarkets, social supply and drug market violence. International Journal of Drug Policy. 2016;35:24-31.




  1. Winstock, Lynskey M, Borschmann R, Waldron J. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. Journal of Psychopharmacology. 2015;29(6):698-703.
  2. Uosukainen H, Tacke U, Winstock AR. Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Int J Drug Policy. 2015;26(1):78-83.
  3. Shiner M, Winstock A. Drug use and social control: The negotiation of moral ambivalence. Social Science & Medicine. 2015;138(0):248-256.
  4. Garnett C, Crane D, West R, Michie S, Brown J, Winstock A. Normative misperceptions about alcohol use in the general population of drinkers: A cross-sectional survey. Addictive Behaviors. 2015;42:203-206.
  5. Freeman TP, Winstock AR. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45(15):3181-3189.
  6. Bellis MA, Quigg Z, Hughes K, Ashton K, Ferris J, Winstock A. Harms from other people’s drinking: an international survey of their occurrence, impacts on feeling safe and legislation relating to their control. BMJ Open. 2015;5(12):1-11.




  1. Winstock AR, Kaar S, Borschmann R. Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. Journal of Psychopharmacology. 2014;28(1):49-54.
  2. Winstock AR, Borschmann R, Bell J. The non-medical use of tramadol in the UK: findings from a large community sample. Int J Clin Pract. 2014;68(9):1147-1151.
  3. Taylor CF, Winstock AR, Olsburgh J. Where next in ketamine uropathy? Dedicated management centres? BJU Int. 2014;114(5):637-638.
  4. Lawn W, Barratt M, Williams M, Horne A, Winstock A. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol. 2014;28(8):780-788.
  5. Ferris J, Winstock A, Devaney M, Waldron J. Nitrous Oxide (N2o) Use and Myeloneuropathy: Understanding the Recreational Use of N2o and the Dose-Response Relationship with Myeloneuropathy. Drug and Alcohol Review. 2014;33:26-26.
  6. Barratt M, Ferris J, Winstock A. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. Addiction. 2014;109(5):774-783.




  1. Winstock AR, Barratt MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharm Clin. 2013;28(4):390-393.
  2. Winstock AR, Barratt MJ. Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Dependence. 2013;131(1-2):106-111.
  3. Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int. 2012;110(11):1762-1766.
  4. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F. Mephedrone, new kid for the chop? Addiction. 2011;106(1):154-161.
  5. Winstock AR, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J. Mephedrone: use, subjective effects and health risks. Addiction. 2011;106(11):1991-1996.
  6. McCambridge J, Mitcheson L, Winstock A, Hunt N. Five-year trends in patterns of drug use among people who use stimulants in dance contexts in the United Kingdom. Addiction. 2005;100(8):1140-1149.
  7. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug and Alcohol Dependence. 2001;64(1):9-17.